In a global cross-sectional sample, ESUS accounted for one-sixth of recent ischemic strokes, typically affecting younger patients with mild strokes who are predominantly treated with antiplatelet therapy.
ESUS accounts for one-sixth of recent ischemic strokes with antiplatelet therapy standard; leaves open whether anticoagulation trials can improve outcomes in this subgroup.
This cross-sectional global sample of patients with recent ischemic stroke shows that one-sixth met criteria for ESUS, with additional ESUS patients likely among those with incomplete diagnostic investigation. ESUS patients were relatively young with mild strokes. Antiplatelet therapy was the standard antithrombotic therapy for secondary stroke prevention in all global regions.
No takes yet. Share an insight, caveat, or question.
Perera et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: